Determinants of Muscle Strength in Chronic Kidney Disease

February 26, 2019 updated by: University Hospital, Montpellier

Aim of this study is to determine in chronic kidney disease patients:

  • the involvement of malnutrition inflammation and atherogenesis syndrome (increase in C reactive protein and decrease in serum albumin) on voluntary muscle strength impairment
  • the relationship between voluntary muscle strength and muscle mass
  • the relationship between voluntary muscle strength and lean body mass
  • the correlation between voluntary muscle strength and physical activity

Study Overview

Detailed Description

Aim of this study is to determine in chronic kidney disease patients:

  • the involvement of malnutrition inflammation and atherogenesis syndrome (increase in C reactive protein and decrease in serum albumin) on voluntary muscle strength impairment (estimated by handheld dynamometer)
  • the relationship between voluntary muscle strength and muscle mass (estimated by creatinine index)
  • the relationship between voluntary muscle strength and lean body mass (estimated by bioelectrical impedance analysis)
  • the correlation between voluntary muscle strength and physical activity (the physical activity being estimated by the "Voorrips" score questionnaire)

Study Type

Interventional

Enrollment (Actual)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34295
        • AIDER
      • Montpellier, France, 34295
        • GCS Help Lapeyronie, CHU Montpellier
      • Nîmes, France, 30900
        • AIDER

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • chronic kidney disease patient with extrarenal replacement therapy by hemodialysis for at least 3 months
  • stable clinical condition (absence of infection, stroke or acute decompensation)

Exclusion Criteria:

  • chronic kidney disease without extrarenal replacement therapy
  • history of renal transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Muscle strength
single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by "Voorrips" score questionnaire), inflammatory and nutritional status.
Evaluation of muscle strength
Evaluation of muscle mass using plasma creatinine level
Evaluation of lean body mass
Evaluation of physical activity
Evaluation of C reactive protein and albumin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Voluntary muscle strength evaluated by handheld dynamometer
Time Frame: 1 day
data will be measured in Newton.meter
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle mass estimated by creatinine index evaluation
Time Frame: 1 day
data will be obtained from plasma creatinine level and will be expressed in milligram/kilogram/day)
1 day
Lean body mass evaluated by electrical bioimpedance analysis
Time Frame: 1 day
data will be expressed in kilogram
1 day
Physical activity estimated using the "Voorrips" score questionnaire
Time Frame: 1 day
the score represents the daily physical activity according to a validated scale
1 day
C reactive protein level
Time Frame: 1 day
the parameter will be measured in milligram/liter
1 day
Albumin level
Time Frame: 1 day
the parameter will be measured in gram/liter
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2016

Primary Completion (Actual)

June 14, 2017

Study Completion (Actual)

October 1, 2017

Study Registration Dates

First Submitted

June 6, 2016

First Submitted That Met QC Criteria

June 15, 2016

First Posted (Estimate)

June 20, 2016

Study Record Updates

Last Update Posted (Actual)

February 28, 2019

Last Update Submitted That Met QC Criteria

February 26, 2019

Last Verified

January 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease

Clinical Trials on Handheld dynamometer

3
Subscribe